Unicycive Therapeutics Inc. $(UNCY)$ has released a new corporate presentation outlining its progress in developing novel treatments for kidney disease. The company's lead asset, OLC, is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, targeting a U.S. market opportunity exceeding $1 billion. Unicycive is currently working towards the resubmission of the OLC New Drug Application (NDA) following a Complete Response Letter from the FDA, which cited issues related to a third-party manufacturing vendor but no concerns with the drug's safety or efficacy. The company has identified a second manufacturing vendor that has already produced OLC drug product and could support the resolution of these issues. Unicycive reports that its team is prepared for commercial launch pending future approval, with ongoing efforts focused on market awareness, reimbursement, and logistics. Additionally, the company is advancing its second asset, UNI-494, for the treatment of acute kidney injury and chronic kidney disease. Unicycive states that it has a cash runway expected to last into the second half of 2026. You can access the full presentation through the link below: [Full Presentation](https://docs.publicnow.com/49E60BEA08DB1ECEDFEDC6E09640A308F4790A86)